Antipsychotics — Typical and Atypical

• Mesolimbic and mesocortical dopamine dysregulation: Schizophrenia involves hyperactivity in the mesolimbic pathway (ventral tegmental area to nucleus accumbens), which drives positive symptoms (hallucinations, delusions), and hypoactivity in the mesocortical pathway (ventral tegmental area to prefrontal cortex), which contributes to negative symptoms (alogia, avolition, anhedonia) and cognitive dysfunction. Typical antipsychotics work primarily through non-selective D2 dopamine receptor antagonism in these limbic regions, effectively reducing positive symptoms. However, their lack of selectivity means they also block D2 receptors in the mesocortical system, potentially worsening negative symptoms. Atypical antipsychotics combine D2 antagonism with potent 5-HT2A serotonin receptor antagonism; the 5-HT2A blockade enhances dopamine release in the prefrontal cortex (through disinhibition of GABAergic interneurons), thereby improving negative symptoms and cognitive function without the degree of mesocortical dopamine blockade seen with typical agents. Different atypical agents show varying degrees of 5-HT2A/D2 binding ratios, which influences their clinical profiles.

• Nigrostriatal dopamine blockade and extrapyramidal effects: The nigrostriatal pathway (substantia nigra to striatum) is crucial for motor control through a balance of dopamine (facilitatory) and acetylcholine (inhibitory). Antipsychotics, particularly typical agents, block D2 receptors in this pathway, shifting the balance toward cholinergic predominance. This produces extrapyramidal side effects including acute dystonia (sustained muscle contractions), akathisia (subjective restlessness), parkinsonism (rigidity, bradykinesia, tremor), and tardive dyskinesia (involuntary choreiform movements emerging after prolonged exposure). The incidence and severity of EPS correlate directly with D2 receptor occupancy; typical antipsychotics achieve >70% striatal D2 occupancy at therapeutic doses, whereas many atypical agents maintain lower striatal occupancy (50-60%) combined with rapid dissociation from D2 receptors (fast off-rate), reducing EPS risk. Additionally, atypical agents' 5-HT2A blockade may counterbalance D2 effects in the striatum, providing neuroprotection against movement disorders.

• Tuberoinfundibular dopamine blockade and prolactin elevation: The tuberoinfundibular pathway (hypothalamus to anterior pituitary) maintains tonic dopamine inhibition of prolactin release. D2 receptor antagonism in this pathway leads to hyperprolactinemia, which causes galactorrhea, gynecomastia, sexual dysfunction, amenorrhea, and decreased bone mineral density. Typical antipsychotics and some atypical agents (particularly risperidone and paliperidone, which have high D2 binding affinity and lower 5-HT2A/D2 ratios) cause significant prolactin elevation. In contrast, quetiapine and aripiprazole produce minimal prolactin elevation due to lower D2 binding affinity or partial agonism, respectively, making these agents preferable for patients at risk for prolactin-related complications.

• Receptor binding diversity in atypical antipsychotics: Beyond D2 and 5-HT2A antagonism, atypical antipsychotics display varying affinities for multiple receptor systems. Clozapine and quetiapine have lower D2 affinity and high affinity for muscarinic M1 and alpha-1 adrenergic receptors, contributing to anticholinergic side effects and orthostatic hypotension. Olanzapine shows broad receptor antagonism including H1 histamine receptors, explaining weight gain and sedation. Aripiprazole is unique as a partial D2 agonist rather than an antagonist; it activates D2 receptors at 25-30% efficacy, providing dopamine stabilization—reducing dopamine activity when elevated (antipsychotic effect) yet maintaining some dopaminergic tone to mitigate negative symptoms and prolactin elevation. This distinct mechanism may explain aripiprazole's favorable metabolic profile and efficacy in maintenance therapy.

• Acute versus chronic neuroadaptation: Initially, antipsychotics acutely block postsynaptic D2 receptors, reducing dopaminergic neurotransmission. However, over 2-4 weeks, neurons undergo compensatory changes including upregulation of D2 receptor expression and increased dopamine synthesis and release. This neuroadaptation contributes to the delayed therapeutic effect observed clinically (4-6 weeks for optimal symptom response), as the system rebalances. Chronic antipsychotic exposure may also enhance GABAergic inhibition in psychosis-relevant circuits and modulate glutamatergic neurotransmission through indirect effects on prefrontal cortex function, mechanisms that may underlie long-term treatment benefits.

• Schizophrenia and schizophreniform disorder: Schizophrenia is a primary psychotic disorder with strong genetic component (heritability ~80%), involving polygenetic inheritance and multiple neurotransmitter system dysregulation beyond dopamine. Environmental risk factors including prenatal factors (maternal infection, nutritional deficiency), developmental factors (childhood trauma, urban living), and substance use (particularly cannabis in adolescence) interact with genetic vulnerability. Schizophreniform disorder represents psychotic symptoms lasting 1-6 months without full schizophrenia criteria. Both warrant antipsychotic treatment to prevent progression and functional decline.

• Bipolar disorder with psychotic features: Bipolar I disorder affects ~1% of the population and frequently presents with psychotic symptoms during manic or depressive episodes. Psychotic features during mood episodes are mood-congruent and require antipsychotic therapy in conjunction with mood stabilizers. Some atypical antipsychotics (e.g., quetiapine, olanzapine, aripiprazole, lurasidone) are FDA-approved for bipolar maintenance and are preferred over typical antipsychotics in this population.

• Delusional disorder and brief psychotic disorder: These conditions represent circumscribed psychotic symptoms (delusions lasting >1 month in delusional disorder, <1 month in brief psychotic disorder). Antipsychotics are therapeutic, though duration may be shorter than in schizophrenia.

• Substance-induced psychosis: Psychosis can emerge acutely from use of stimulants (cocaine, amphetamines, methamphetamine), hallucinogens (LSD, psilocybin), dissociatives (PCP, ketamine), or excessive alcohol/benzodiazepine withdrawal. Antipsychotics may be needed acutely but often can be withdrawn after resolution of intoxication or withdrawal state. Cannabis use, particularly in individuals with genetic predisposition, can precipitate lasting psychotic illness.

• Psychosis secondary to medical conditions: Medical causes requiring antipsychotic treatment include neurodegenerative diseases (Parkinson's disease with psychosis, Lewy body dementia), neuroinflammatory conditions (encephalitis), endocrine disorders (hyperthyroidism, adrenal insufficiency), autoimmune conditions, and neoplasms. In Parkinson's disease, typical antipsychotics are contraindicated due to D2 blockade worsening motor symptoms; quetiapine or pimavanserin (5-HT2A inverse agonist) are preferred.

• Antipsychotic-naïve versus treatment-resistant populations: First-episode psychosis patients tend to respond robustly to antipsychotics (60-70% response rate), making this population most responsive. Treatment-resistant schizophrenia (defined as inadequate response to ≥2 antipsychotics at adequate doses for adequate duration) occurs in ~30% of schizophrenia cases and requires clozapine, the only agent with proven efficacy in this population through unique pharmacological properties including strong D1 antagonism relative to D2, muscarinic M1 agonism, and GABA modulation.

• Positive symptoms (hallucinations and delusions): These represent excess or distortion of normal experiences. Auditory hallucinations (hearing voices, often commanding or accusatory) are the most common hallucination type in schizophrenia and respond well to antipsychotics within days to weeks. Visual hallucinations are less common but also respond to treatment. Delusions (false, fixed beliefs despite contradictory evidence) may be paranoid (beliefs of persecution), referential (belief that unrelated events have personal significance), grandiose (inflated self-importance), or somatic. Antipsychotics are highly effective for positive symptoms, with response rates of 60-80% in first-episode patients. Delusional intensity decreases typically before complete resolution occurs.

• Negative symptoms (avolition, alogia, anhedonia, affective blunting): These represent deficiency or loss of normal functions and respond more poorly to antipsychotics than positive symptoms, though atypical agents offer superior efficacy compared to typical agents. Avolition (lack of motivation and goal-directed behavior) manifests as poverty of speech, decreased engagement, and functional decline. Alogia (poverty of speech and thought) presents as laconic responses and reduced spontaneous speech. Anhedonia (inability to experience pleasure) leads to social withdrawal and reduced engagement in previously enjoyed activities. Affective blunting (restricted emotional expression and responsiveness) gives an appearance of emotional indifference despite internal experience. Negative symptoms correlate more strongly with prefrontal cortex dopamine hypoactivity and respond better to atypical antipsychotics that enhance prefrontal dopamine through 5-HT2A blockade.

• Cognitive dysfunction: Schizophrenia involves impairments in working memory, attention, processing speed, and executive function. These cognitive deficits often precede psychotic symptom onset and persist despite antipsychotic treatment of positive symptoms. Cognitive improvements are more pronounced with atypical antipsychotics, particularly those with lower D2 occupancy and enhanced 5-HT2A antagonism. This cognitive domain is underappreciated in clinical practice but significantly impacts functional outcome and quality of life.

• Disorganized symptoms: Disorganized speech and behavior, including tangentiality, derailment, pressured speech, and psychomotor agitation, are prominent in some patients. Disorganized speech reflects formal thought disorder and responds moderately to antipsychotics. Catatonia (waxy flexibility, mutism, posturing, negativism) may occur in severe psychosis and typically responds within days to antipsychotics or benzodiazepines.

• Catatonic features: Catatonia, historically more common but still seen in acute psychosis, presents as motor rigidity, decreased responsiveness, waxy flexibility, mutism, posturing, or echokinesis (automatic imitation of movements). This represents the severe end of the psychotic spectrum and requires urgent antipsychotic and sometimes benzodiazepine intervention.

• Affective symptoms: Depression and anxiety commonly co-occur with psychosis in both schizophrenia and bipolar disorder. Some antipsychotics have anxiolytic properties (quetiapine, particularly), while others may worsen mood through dopamine blockade. Suicidality is elevated in first-episode psychosis and requires careful monitoring, especially early in treatment when patients gain insight into their illness.

• Physical examination findings: Patients with acute psychosis may exhibit psychomotor agitation, poor hygiene and grooming, inappropriate affect, or catatonic features. Baseline examination is essential for antipsychotic-naïve patients to detect preexisting movement disorders. Historical information about family psychiatric history, substance use, and stressors provides clinical context.

• DSM-5 diagnostic criteria for schizophrenia: Diagnosis requires ≥2 of 5 symptom domains (delusions, hallucinations, disorganized speech, disorganized or catatonic behavior, negative symptoms) present for ≥1 month with ≥6 months total duration including prodromal symptoms, causing functional decline, and with exclusion of substance use and medical causes. At least one symptom must be delusion, hallucination, or disorganized speech (first-rank symptoms). The PANSS (Positive and Negative Syndrome Scale) is the gold standard for rating symptom severity, with subscales assessing positive symptoms (score 7-49), negative symptoms (score 7-49), and general psychopathology (score 16-112); scores correlate with antipsychotic response and are used in clinical trials but are less practical in routine clinical care.

• Psychiatric history and mental status examination: Comprehensive psychiatric evaluation should assess onset (acute vs insidious), timeline of symptom progression, presence of prodromal features (social withdrawal, declining functioning, perceptual disturbances), functional impact, substance use history (particular attention to cannabis, stimulants, hallucinogens, and alcohol), family history of psychiatric illness, medical comorbidities, and current medications. Mental status examination documents appearance, speech pattern, mood and affect, thought process (formal thought disorder), thought content (delusions, obsessions), perception (hallucinations), cognition (alertness, orientation, memory, concentration, abstract thinking), insight and judgment, and suicidality/homicidality.

• Laboratory evaluation for first-episode psychosis: Baseline labs should include complete metabolic panel (CMP) for glucose, lipids, and renal function; prolactin level; fasting glucose or hemoglobin A1C; lipid panel (total cholesterol, LDL, HDL, triglycerides); weight and BMI; electrocardiogram (ECG) to assess QT interval, particularly important for antipsychotics with QT prolongation risk (haloperidol, risperidone, paliperidone, sertindole); and urine pregnancy test in females of childbearing potential. These establish baseline metabolic parameters given antipsychotic-associated weight gain and metabolic syndrome. Prolactin baseline is particularly important for agents expected to elevate it (typical antipsychotics, risperidone, paliperidone).

• Neuroimaging: While not required for diagnosis in most cases, brain MRI can exclude structural lesions, particularly in first-episode psychosis with atypical features (focal neurological signs, progressive course, late-life onset, or unilateral symptoms). Structural abnormalities in schizophrenia are nonspecific but include reduced gray matter volume, ventricular enlargement, and decreased frontal lobe volume; these are present in some but not all patients and are not diagnostic. Neuroimaging is indicated when there is clinical suspicion of secondary psychosis from mass, hemorrhage, or infarction.

• Exclusion of medical and substance-induced causes: Toxicology screening (urine drug screen) is essential to rule out stimulant-induced, hallucinogen-induced, or dissociative-induced psychosis. Thyroid function (TSH, free T4) excludes hyperthyroidism or myxedema. Syphilis serology (RPR/VDRL) should be obtained, particularly in patients with late-

Movement toxicity (nigrostriatal D2 blockade), by time course

• Acute dystonia (hours to days): sustained torticollis, trismus, oculogyric crisis, laryngospasm; highest risk in young men on high-potency typicals (haloperidol, fluphenazine). Reverse with an anticholinergic (benztropine) or antihistamine (diphenhydramine), given IM for airway-threatening cases.
• Akathisia (days to weeks): inner restlessness with pacing; mechanistically dopaminergic, not anxiety. Reduce dose or switch; beta blockers (propranolol) or a benzodiazepine are used adjunctively.
• Drug-induced parkinsonism (weeks): bradykinesia, cogwheel rigidity, tremor from >70–80% striatal D2 occupancy. Dose reduction, switch to a lower-potency/atypical agent, or anticholinergic.
• Tardive dyskinesia (months to years): choreoathetoid orobuccolingual movements from postsynaptic D2 supersensitivity/upregulation; often irreversible. FDA-approved VMAT2 inhibitors (valbenazine, deutetrabenazine) are the evidence-based treatment; anticholinergics worsen it.

• Young man, first haloperidol dose, neck twisted or eyes rolled upward: acute dystonia/*oculogyric crisis*. Single best next step is IM benztropine or diphenhydramine — not dose escalation, not a benzodiazepine alone.
• "Can't sit still, keeps pacing": akathisia, the classic distractor for worsening psychotic agitation. Increasing the antipsychotic makes it worse; lower the dose, switch, or add propranolol.
• Rigidity + fever + autonomic instability + high CK is NMS (lead-pipe rigidity, hyporeflexia, days-long onset). The examiner's contrast is serotonin syndrome: clonus and hyperreflexia, onset within hours, treated with cyproheptadine. NMS antidotes are dantrolene and a dopamine agonist.
• Treatment-resistant schizophrenia (failure of ≥2 adequate trials) → clozapine, the one agent with proven efficacy here and the only one shown to reduce suicidality in schizophrenia. The price is mandatory ANC monitoring under the Clozapine REMS, plus myocarditis, seizures, sialorrhea, and constipation/ileus.
• Metabolic hierarchy: clozapine and olanzapine are the worst offenders for weight gain, dyslipidemia, and new-onset diabetes; aripiprazole, ziprasidone, and lurasidone are the metabolically favorable choices. ADA/APA consensus monitoring of weight, glucose/A1c, lipids, and blood pressure is a frequently tested "next step."
• Galactorrhea, amenorrhea, or gynecomastia on risperidone = tuberoinfundibular D2 blockade with hyperprolactinemia. Check prolactin, then switch to aripiprazole (partial D2 agonist) or quetiapine.
• Tardive dyskinesia gets a VMAT2 inhibitor (valbenazine or deutetrabenazine). Adding an anticholinergic is the trap — it helps parkinsonism and dystonia but aggravates TD.
• Psychosis in Parkinson disease or Lewy body dementia: use quetiapine or pimavanserin; D2-blocking agents precipitate severe motor deterioration. Remember the FDA boxed warning of increased mortality when any antipsychotic is used for dementia-related psychosis.